Related Experiment Videos
Beta-blockade in chronic dialysis patients
Seth B Furgeson1, Michel Chonchol
1Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Insights
Cardiovascular diseases (CVD) cause half of deaths in dialysis patients. Beta-blockers may help, but their effectiveness and safety in this population require further investigation.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Cardiovascular diseases (CVD) are a leading cause of mortality in chronic dialysis patients, accounting for approximately 50% of deaths.
- Sudden cardiac death is prevalent, representing 60% of cardiac deaths in this population, often linked to conditions like cardiomyopathy, coronary artery disease, and arrhythmia.
- Despite dialysis advancements, CVD mortality remains high due to a lack of evidence-based strategies for managing cardiac conditions.
Purpose of the Study:
- To review the role of sympathetic nervous system activation in the pathogenesis of cardiovascular diseases in chronic kidney disease (CKD) patients.
- To evaluate the potential benefits and risks of beta-blocker therapy in patients undergoing chronic dialysis.
- To address the uncertainty surrounding beta-blocker efficacy and usage in the dialysis population.
Main Methods:
- Literature review focusing on sympathetic nervous system activation in kidney disease.
- Analysis of studies investigating beta-blocker use in patients with advanced chronic kidney disease and on dialysis.
- Examination of potential benefits (e.g., reducing cardiovascular morbidity and mortality) versus risks (e.g., hypotension, bradycardia, hyperkalemia).
Main Results:
- Sympathetic adrenergic system activation is a documented issue in chronic dialysis patients, contributing to cardiac pathologies.
- Beta-blockers have demonstrated benefits in non-dialysis patients with similar cardiac conditions.
- Evidence regarding the efficacy and safety of beta-blockers in the chronic dialysis population remains unclear, with concerns about suboptimal usage.
Conclusions:
- Beta-blockers present a potential therapeutic option for reducing cardiovascular risk in dialysis patients due to sympathetic overactivity.
- However, the specific benefits and risks, including side effects like hypotension and hyperkalemia, need careful consideration in this vulnerable group.
- Further research is essential to clarify the role and optimize the use of beta-blockers in patients with advanced chronic kidney disease undergoing dialysis.
Abstract:
Approximately 50% of the mortality in chronic dialysis patients is due to cardiovascular diseases (CVD). Cardiomyopathy, coronary artery disease, and arrhythmia are all common conditions and predispose to sudden death, which accounts for 60% of all cardiac deaths in this population. Despite advances in dialysis therapy, the mortality from CVD remains substantially unchanged, partly due to the lack of evidence-based strategies for improving the outcome of cardiac diseases in this population. Activation of the sympathetic adrenergic system is well documented in chronic dialysis patients and is likely involved in the pathogenesis of myocardial hypertrophy, coronary artery disease, heart failure, and arrhythmia. Given the proven benefit of beta-blockers in patients with normal kidney function with similar cardiac comorbidities, beta-blockers would seem to be attractive agents to reduce cardiovascular morbidity and mortality in the patient population with advanced chronic kidney disease. However, the value of beta-blockade in patients on chronic dialysis remains unclear. This uncertainty surrounding the efficacy is compounded by the risk of side effects to these patients, such as hypotension, bradycardia, and hyperkalemia. In addition, numerous studies have suggested suboptimal usage of beta-blockers in the dialysis population; this is seen even in high risk patients, such as those with established coronary artery disease. In this review, we will focus on sympathetic nervous system activation in kidney disease and highlight the benefit and risks of beta-blockers usage in the chronic dialysis patient population.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Chronic Kidney Disease III: Interprofessional Care
01:22Heart Failure Drugs: β-Blockers
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
01:18Chronic Kidney Disease IV: Nursing Management
01:17Antihypertensive Drugs: Action of β1 Blockers